The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue , 2014, Pages 1-10

  Blandizzi, C ^a   Gionchetti, P ^b   Armuzzi, A ^c   Caporali, R ^d   Chimenti, S ^e   Cimaz, R ^f   Cimino, L ^g   Lapadula, G ^h   Lionetti, P ^f   Marchesoni, A ⁱ   Marcellusi, A ^e   Mennini, F S ^e   Salvarani, C ^j   Girolomoni, G ^k  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g Ophthalmology Unit   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ G Pini Orthopaedic Institute   (Italy)

^j S MARIA NUOVA HOSPITAL   (Italy)

^k UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

immune mediated inflammatory disease; pathogenesis; Tumour necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; ANIMAL; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900807640     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/03946320140270S101     Document Type: Review

References (63)

1. Firestein G.S., Corr M., Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl 2005; 73: 8-13; discussion 29-30.
2. Ng S.C., Bernstein C.N., Vatn M.H., et al.Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-49.
3. Kuek A., Hazleman B.L., Ostor A.J., Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007; 83: 251-60.
4. Williams J.P., Meyers J.A., Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs. Am J Manag Care 2002; 8: S664-81; quiz S82-5.
5. Nash P.T., Florin T.H., Tumour necrosis factor inhibitors. Med J Aust 2005: 183: 205-8.
6. Silva L.C., Ortigosa L.C., Benard G., Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. Immunotherapy 2010; 2: 817-33.
7. Robinson D. Jr., Hackett M., Wong J., Kimball A.B., Cohen R., Bala M., Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: An exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006; 22: 989-1000.
8. El-Gabalawy H., Guenther L.C., Bernstein C.N., Epidemiology of immune-mediated inflammatory diseases: Incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 2010; 85: 2-10.
9. Vizcarra C., New perspectives and emerging therapies for immune-mediated inflammatory disorders. J Infus Nurs 2003; 26: 319-25.
10. Yeh S., Karne N.K., Kerkar S.P., et al.Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009; 116: 981-89 e1.
11. Cihakova D., Rose N.R., Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008; 99: 95-114.
12. Ng S.C., Tang W., Ching J.Y., et al.Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013; 145: 158-65 e2.
13. Glas J., Stallhofer J., Ripke S., et al.Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009; 104: 1737-44.
14. Jacobs P., Bissonnette R., Guenther L.C., Socioeconomic burden of immune-mediated inflammatory diseases-focusing on work productivity and disability. J Rheumatol Suppl 2011; 88: 55-61.
15. Filipovic I., Walker D., Forster F., Curry A.S., Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1083-90.
16. Boonen A., Mau W., The economic burden of disease: Comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S112-7.
17. Zink A., Thiele K., Huscher D., et al.Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 86-90.
18. Franke L.C., Ament A.J., van de Laar M.A., Boonen A., Severens J.L., Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S118-23.
19. Mewar D., Wilson A.G., Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011; 162: 785-91.
20. Remouchamps C., Boutaffala L., Ganeff C., Dejardin E., Biology and signal transduction pathways of the Lymphotoxin-alphabeta/LTbetaR system. Cytokine Growth Factor Rev 2011; 22: 301-10.
21. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P., Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-79.
22. Horiuchi T., Mitoma H., Harashima S., Tsukamoto H., Shimoda T., Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49: 1215-28.
23. Kozuch P.L., Hanauer S.B., General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 757-73.
24. Thalayasingam N., Isaacs J.D., Anti-TNF therapy. Best practice & research Clinical rheumatology 2011; 25: 549-67.
25. Arend W.P., Dayer J.M., Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15.
26. Saxne T., Palladino M.A. Jr., Heinegard D., Talal N., Wollheim F.A., Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5.
27. Brennan F.M., Chantry D., Jackson A., Maini R., Feldmann M., Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7.
28. Knight D.M., Trinh H., Le J., et al.Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
29. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G., Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. Embo J 1991; 10: 4025-31.
30. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., Palladino M.A., Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992; 89: 7375-9.
31. Williams R.O., Feldmann M., Maini R.N., Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8.
32. Papadakis K.A., Targan S.R., Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57.
33. Sartor R.B., Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
34. Braegger C.P., Nicholls S., Murch S.H., Stephens S., MacDonald T.T., Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
35. Murch S.H., Braegger C.P., Walker-Smith J.A., MacDonald T.T., Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9.
36. Corazza N., Brunner T., Buri C., Rihs S., Imboden M.A., Seibold I., Mueller C., Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004; 127: 816-25.
37. Nakai M., Sudo K., Yamada Y., et al.The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig Dis Sci 2005; 50: 1669-76.
38. Tilg H., Moschen A., Kaser A., Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2007; 7: 1051-9.
39. Fantuzzi F., Del Giglio M., Gisondi P., Girolomoni G., Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008; 12: 1085-96.
40. Chomarat P., Dantin C., Bennett L., Banchereau J., Palucka A.K., TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003; 171: 2262-9.
41. Cumberbatch M., Dearman R.J., Griffiths C.E., Kimber I., Langerhans cell migration. Clin Exp Dermatol 2000; 25: 413-8.
42. Ritter U., Meissner A., Ott J., Korner H., Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF. J Leukoc Biol 2003; 74: 216-22.
43. Fraticelli P., Sironi M., Bianchi G., et al.Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-81.
44. Mascia F., Mariani V., Girolomoni G., Pastore S., Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-12.
45. Pastore S., Mascia F., Mariani V., Girolomoni G., The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008; 128: 1365-74.
46. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., Rowan A.D., Interleukin 17 induces cartilage collagen breakdown: Novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002; 61: 704-13.
47. D O.G. Ireland D., Bord S., Compston J.E., Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004; 63: 354-9.
48. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., Schwarz E.M., Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31.
49. Wen Z., Fiocchi C., Inflammatory bowel disease: Autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004; 11: 195-204.
50. McInnes I.B., Schett G., The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
51. Vicente E.F., Hernandez-Nunez A., Aspa J., Aragues M., Garcia-Vicuna R., Crohn's disease, relapsing polychondritis and epidermolysis bullosa acquisita: An immune-mediated inflammatory syndrome. Rheumatology (Oxford) 2008; 47: 380-1.
52. Weng X., Liu L., Barcellos L.F., Allison J.E., Herrinton L.J., Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol 2007; 102: 1429-35.
53. Kappelman M.D., Galanko J.A., Porter C.Q., Sandler R.S., Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011; 96: 1042-6.
54. Cruz V.A., Yamaguchi L., Ribeiro C.N., Vde O. Magalhaes, Rego J., Silva N.A., Ulcerative colitis and rheumatoid arthritis: A rare association-case report. Rev Bras Reumatol 2012; 52: 648-50.
55. Rebelo A., Leite S., Cotter J., Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab. BioDrugs 2010; 24 Suppl 1: 37-9.
56. Li W.Q., Han J.L., Chan A.T., Qureshi A.A., Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2012.
57. Steinwurz F., Denadai R., Saad-Hossne R., Queiroz M.L., Teixeira F.V., Romiti R., Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohns Colitis 2012; 6: 610-6.
58. Cohen A.D., Dreiher J., Birkenfeld S., Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-5.
59. Helmick C.G., Felson D.T., Lawrence R.C., et al.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15-25.
60. Symmons D., Turner G., Webb R., et al.The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800.
61. Myasoedova E., Crowson C.S., Kremers H.M., Therneau T.M., Gabriel S.E., Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62: 1576-82.
62. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M., Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
63. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P., Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii14-7.